This company has shut down. Glympse Bio is no longer operating — its last tracked round was a Venture - Series Unknown in 2021.
Explore the Startup GraveyardGlympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
Glympse Bio has raised $18.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2021.
Glympse Bio's investors include Temasek, Alumni Ventures, ARCH Venture Partners, Catalio Capital Management, Gilead Sciences.
Glympse Bio is headquartered in Cambridge, United States.
Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
Glympse Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Glympse Bio — Funding & Investors." VCBacked, December 17, 2021, https://www.vcbacked.co/company/glympse-bio. Accessed August 14, 2026.
VCBacked. (2021). Glympse Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/glympse-bio
{{cite web |title=Glympse Bio — Funding & Investors |url=https://www.vcbacked.co/company/glympse-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated